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ABSTRACT 
West Nile virus (WNV) was first detected in New Mexico in 2002, with the first human 
cases appearing in 2003. Since that time it has become endemic in the region, and as of 
year-end 2005, 330 New Mexicans had been diagnosed with West Nile Fever or the more 
severe neuroinvasive disease as reported by the New Mexico Department of Health. An 
ongoing study at the University of New Mexico has collected interview and physical 
exam data for these individuals as well as collecting cerebrospinal fluid (CSF) and serum 
from their period of acute and convalescent illness. While all of these samples have been 
tested to determine WNV IgM seropositivity, none of them have been characterized by 
the use of nucleic acid amplification test (NAT). The purpose of this study is to 
characterize this sample set using Real-Time reverse transcriptase polymerase chain-
reaction (RT-PCR), an extremely sensitive NAT. The serum and CSF archived collection 
at UNM represents one of the most comprehensive and best-characterized sample sets 
available in the United States. A total of 115 samples, 111 serum and 4 CSF, were 
analyzed. None of the 115 samples had detectable West Nile nucleic acid.   
 
INTRODUCTION 
West Nile virus (WNV) is a member of the genus Flavivirus. Significant Flavivirus 
species include yellow fever, dengue, and a complex of encephalitis viruses among which 
West Nile is included. WNV is an enveloped single-stranded positive-sense RNA virus. 
The genome is approximately 11,000 nucleotides and contains a 5’ non-coding region, 
followed by capsid, envelope, and membrane protein coding regions, and seven non-
structural protein coding regions (Campbell, et al). Differences in WNV pathogenicity 
may be attributable to nucleotide mutations in the membrane, envelope, or non-structural 
protein coding regions of the WNV genome (Beasley, et al). 
British virologists first characterized WNV from the blood of a febrile woman in 
the West Nile region of Uganda in 1937 (Smithburn, et al).  The same virus was later 
isolated from 3 children experiencing a mild febrile disease, thus WNV was established 
as a human pathogen (Melnick, et al). WNV was found to cycle between Culicine 
mosquitoes and native birds, with birds being the natural amplifying host and humans 
secondary hosts.  For decades WNV was felt to produce only a fairly mild dengue-like 
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human illness with fever, malaise, lymphadenopathy and rash.  A 1951 Israeli outbreak of 
WNV typified these characterizations of WNV as a self-limited mild febrile illness 
without sequelae (Goldblum, et al). The cases of encephalitis and death which now 
appear in cases of human WNV infection were rarely seen until the mid 1990s when an 
apparent change in virulence occurred demonstrated by outbreaks of severe encephalitis 
in Romania, Russia, Israel, and Algeria. Up to 60% of the patients in these outbreaks 
presented with neuroinvasive disease. The mortality rate was 4-7% resulting from 
neurologic damage.  
WNV was first detected in the Americas in New York City in 1999. Genetic 
sequencing showed that the virus showed almost total homology with an Israeli strain of 
the virus (Lanciotti, Roehrig, et al). It is presumed the virus came from an infected bird 
illegally transported into the United States. Since that date over 16,000 cases of WNV 
and 660 deaths due to WNV have been reported in the United States as of 2004. The 
CDC reported that neuroinvasive disease was present in over 30% of the reported cases 
since that date. WNV has spread from coast to coast since the New York outbreak, and 
human cases have now been reported across the United States and Canada. The WNV 
epidemic has become the largest outbreak of human arboviral encephalitis in North 
America (Soloman, et al). The state of New Mexico experienced an initial outbreak of 
209 reported cases of WNV in 2003 and the disease has been endemic since that time—
with 88 cases confirmed by the New Mexico Department of Health in 2004 and 33 cases 
in 2005.  
The clinical picture of WNV infection in the United States today shows that 
approximately 80% of infected individuals experience asymptomatic infection with 
WNV (Mostashari, et al). The majority of symptomatic individuals experience a self-
limited illness characterized by acute fever, malaise, headache, fatigue, muscle pain, and 
weakness. These symptoms known as ‘West Nile fever,’ are severe, but self limited. The 
disease was originally felt to last less than one week, however new data, including the 
comprehensive New Mexico study, clearly indicate patients may experience symptoms 
such as fever for several weeks, and fatigue for up to one year post-infection.  In less than 
1% of individuals, neuroinvasive disease occurs leading to meningitis, encephalitis, and 
myelitis as possible outcomes (Mostashari, et al). Patients diagnosed with neuroinvasive 
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disease often present with focal neurologic deficits for months to years (Sejvar, et al). 
Neuroinvasive WNV is also associated with a 9% mortality rate (O’Leary, et al). 
West Nile diagnostics have focused on serological tests of WNV-specific IgM 
correlated with a clinical history. For most patients, WNV IgM antibody persists in serum 
for 3-6 months and is replaced by WNV IgG antibody, which is very long lasting.  As a 
consequence of the short duration of WNV IgM antibody, its presence in serum or CSF 
has been used to establish a diagnosis of an acute or recent infection. Because of long-
term IgM persistence in WNV infected humans, IgM alone cannot be used as a marker of 
acute disease. IgM is present in 36% of patients 12 months after clinical disease (Roehrig, 
et al). Diagnosis can also be made by detection of virus in CSF, serum, or tissue using 
nucleic acid amplification tests (NAT). The most effective of these requires inoculation 
of cell culture or mice and subsequent reverse transcriptase amplification of the virus 
from these tissues (Hayes et al). Direct amplification of viral RNA from patient CSF and 
serum has proven to be less reliable. Real-Time reverse transcriptase PCR (RT-PCR) 
appears to be the best NAT for direct amplification of viral RNA showing, in one trial, 
detection of WNV at quantities less than 1 plaque-forming unit (PFU) (Lanciotti, et al).  
Dr. Diane Goade’s lab at the University of New Mexico currently houses the 
largest collection of acute West Nile CSF, blood and serum in the United States. Our 
study will consist of screening these acute samples with RT-PCR. All of the samples 
have been previously assessed by serologic methods, confirming West Nile IgM 
antibody. With a sample size of 77 acute specimens and 38 convalescent specimens, this 
will be among the largest Real-Time PCR surveys of acute West Nile CSF and serum 
done to date. While previous data suggests that finding viral nucleic acid in human 
specimens is unlikely, this is the most sensitive test for such analysis. We feel pursuit of 
this screening is important to help us understand if the long-term elevation of IgM and 
IgG seen in many of these samples is related to persistent or relapsing viremia.   
 
METHODS 
Sample Acquisition: 
Samples have been collected as a part of an ongoing longitudinal WNV study underway 
at the University of New Mexico. Specimens were collected between 2003 and 2007. 
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Samples from both the acute phase (day 1-30) and convalescent (day 31 and up) of 
patient illness were available for analysis. Patient samples have been approved under 
HRRC Approval form 03-445. The HRRC has approved the samples to be used for 
nucleic acid analysis.  
 RNA extracted from serums of WNV-negative volunteers was used for negative 
controls. These samples were obtained with volunteer consent under HRRC Approval. 
 
Sample Processing: 
The specimens were processed and stored under pre-PCR conditions in a dedicated -80°C 
freezer. WNV infection was confirmed on all samples by identification of WNV-specific 
IgM and IgG using ELISA (Focus Technologies). RNA was isolated directly from patient 
CSF and serum using the QIAamp viral RNA mini-kit (Qiagen). Nucleic acid yield from 
the isolation was verified on all samples using the NanoDrop 1000 UV/Vis 
Spectrophotometer (Thermo Scientific). 
 
Real-Time Quantitative PCR assay:  
The Real-Time Quantitative PCR (RT-PCR) assay was performed using the ABI Prism 
7000 (PE Applied Biosystems). Primers and probes recognizing WNV-specific RNA 
sequences were used as described by Lanciotti, et al.  Samples were amplified using 
TaqMan Gold RT-PCR reagents (Applied Biosystems) per the manufacturer’s 
specifications. All samples were run in duplicate.  
 
Controls: 
The positive control RNA was provided by Dr. Greg Ebel. Stock virus in the positive 
control had 4.0x108 PFU per 0.1mL. A standard curve was produced from serial tenfold 
dilutions of RNA extracted from this stock (Figure 1).  
Negative control RNA was extracted from serums of WNV-negative volunteers. 
 
RESULTS 
A total of 115 acute and convalescent samples were analyzed. Samples defined as ‘acute’ 
were obtained between day #1 and day #30 of the patients’ illness, day #1 being the 
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earliest blood sample taken on a patient’s day of presentation. This designation is 
consistent with clinical determinants of acute disease—where manifestations of 
measurable acute disease are present until day #30.  We analyzed 77 acute patient 
samples (4 CSF and 73 serum samples) and 38 convalescent (all serum) patient samples.  
 None of the samples, acute or convalescent, were positive upon analysis with RT-
PCR. All samples were run in duplicate to assure accurate interpretation. Amplification 
results from a sample set of acute samples are shown in Figure 1.  This figure 
demonstrates successful amplification of the positive control dilutions (in duplicate) at 
1x107, 1x106, 1x105, 1x104, 1x103 PFU equivalents, respectively, from left to right.  The 
positive controls are the only samples in Figure 1 that pass the green threshold line.  In a 
positive RT-PCR reaction a sample will pass the green threshold line demonstrating 
presence of West Nile virus nucleic acid. The patient samples in this figure are each a 
different color and present as either jagged lines (negative samples) or as lines with a 
gradual slope that do not reach the threshold (negative samples with fluorescence 
artifact).  
Figure 2 shows a Standard Curve based on the samples shown in Figure 1, with 
an R-value of 0.998079. The data retrieved from assays of the other samples, both acute 
and convalescent, were similar to these findings.  
 
DISCUSSION 
Our analysis showed a total of 115 samples, both acute and convalescent, serum 
and CSF, negative upon attempted amplification with RT-PCR. All of these samples had 
been previously tested with ELISA. All samples acute and convalescent, had IgM 
response and many had IgG as well. Because of this, there was reason to believe finding 
virus in any of these samples would be rare. However, we pursued this research to help us 
understand if the long-term elevation of IgM and IgG seen in many of these samples was 
related to persistent or relapsing viremia. Because our sample size was significantly 
larger than similar studies, we felt that we would have additional power to observe such a 
phenomenon should it exist. Whether such a phenomenon would be observable or not 
remains in question. Because we were not able to detect WNV nucleic acid in even our 
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most acute samples, casts doubt that any reappearance of virus in a convalescent sample 
would be observable with this technique. 
We feel that the assay was robust and performed properly. It should be noted that 
our positive controls were positive and negative controls negative consistently as was 
expected. We diluted our positive control to 1x101 with successful amplification showing 
our ability to amplify WNV from low viral load samples. It has been reported that a 
minimum of 40 viral copies/mL are necessary for Real-Time PCR amplification 
(Lanciotti). We also ‘spiked’ negative control RNA with dilute positive control RNA to 
assure that the amount of non-viral RNA in a sample did not inhibit the reaction in these 
‘spiked’ samples.  Thus, we believe that if there was detectable WNV nucleic acid in the 
samples, our assay would have been able to amplify it. In addition, sample processing 
and storage was performed according to commonly accepted protocol.  
 Table 1 shows confidence intervals for both our acute and convalescent samples. 
For the acute specimens (N=77) we would not expect more than 4.68% difference in 
results if repeated (CI=0-4.68%). For the convalescent specimens (N=38) we would not 
expect more than 9.25% difference in results if repeated (CI=0-9.25%). 
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TABLES 
 
Table 1.  Confidence Intervals based on Number of Samples  
 # Samples Tested % Positive (Confidence Interval) 
Acute Samples 77 0  (0-4.68) 
Convalescent Samples 38 0  (0-9.25) 
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FIGURES 
 
Figure 1.  RT-PCR Sample Flourescence by Cycle  
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Figure 2.  RT-PCR Standard Curve for Samples in Figure 1.  
 
